Skip to main content
Premium Trial:

Request an Annual Quote

UK's Babraham Institute Opens New Bioincubator Building, Expanding Space for Startups

By Alex Philippidis

NEW YORK (GenomeWeb News) – The commercial arm of the UK's Babraham Institute has expanded its bioincubator space by 8,000 square feet following the opening of its £4 million ($6.4 million) Maia building within its campus.

Babraham Bioscience Technologies Ltd. has attracted seven companies to the space, spokeswoman Claire Cockcroft told GenomeWeb Daily News. Synome, Recombinant Antibody Technology, and Convergence Pharmaceuticals are new arrivals to the Babraham Research Campus located some 6 miles south of Cambridge, let alone Maia. Another four other companies have relocated to Maia from smaller spaces within the campus — Innova Biosciences, Total Scientific, Urosens, and Alpha Biologics.

Those companies, and future tenant businesses at Maia, will have access to the Technology Development Laboratory, a biology and chemistry laboratory designed for proof-of-concept stage users in molecular biology, protein biochemistry, cell biology, and medicinal and synthetic chemistry.

The new space, as with current incubator space, will be open to startups whether spun out of the institute or from elsewhere.

With the opening of Maia, the campus now has about 70,000 square feet of total bioincubator space for startups.

The new building was originally planned as the first of two "Maia" phases; Cockcroft had no information on the status of the second phase.

A ceremony marking the completion of Maia was held last week, following the delivery of the 2010 Bioenterprise Lecture by Sir Gregory Winter.

Funding for the Maia building came from the Biotechnology and Biological Sciences Research Council, which supports the Babraham Institute.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.